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Abstract 
Rare  tumor  research  presents  many  chal-
lenges.  Large,  randomized  clinical  trials  are
often impractical in this field and access to
biospecimens may be problematic. These diffi-
culties can best be addressed through multi-
disciplinary, national and international collab-
orative efforts among researchers, clinicians,
governmental bodies, and patients. Numerous
governmental and private organizations now
exist  to  facilitate  cooperation  between
researchers and institutions. Patient advocacy
organizations now play an increasingly impor-
tant  role  in  partnering  with  traditional
research  groups  to  promote  rare  tumor
research. Rare  Tumors is  now  beginning  an
editorial  series  focusing  on  the  problems  of
rare  tumor  research.  We  wish  to  invite  all
researchers and clinicians who are involved in
rare  tumor  research  and  treatment  to  con-
tribute their observations on the problems of
working in this field, either as a letter to the
editor, an editorial on a select issue, or as a
review paper. 
With this issue, Rare Tumors begins a series
of  editorials  and  reviews  focusing  on  the
“problem”  of  rare  tumor  study  and  clinical
care.  Rare  tumor  research  presents  many
inherent challenges. Simply finding a consen-
sus  on  the  definition  of  what  constitutes  a
“rare tumor” is in itself a difficult prospect. In
the United States, “rare” diseases are defined
by the National Institutes of Health Office for
Rare Diseases as those having a prevalence of
200,000 individuals or less. Subtypes of com-
mon cancers, such as adenoid cystic carcino-
ma of the breast, can also be considered rare if
they meet this definition.
1 In Europe, rare dis-
eases are defined as those affecting 1 in 2,000
citizens  of  the  European  Union.
2 Although
individual rare diseases may be infrequently
encountered, rare diseases in aggregate affect
tens  of  millions  of  individuals  in  the  US,
Europe and worldwide.
3 As our understanding
of  the  genetic  basis  for  rare  illnesses  and
tumors grows, it is likely that our conception of
what  is  a  rare  disease  will  undergo  further
transformation  and  expansion  as  neoplasms
are  subdivided  into  ever  finer  categories.  A
recent example of this trend is the recognition
of the significance of the presence of IDH1 and
IDH2  mutations  in  human  gliomas.  In  that
case,  the  identification  of  mutations  in  two
NADP
+-dependent  isocitrate  dehydrogenase
genes  has  had  important  prognostic  signifi-
cance  in  differentiating  subtypes  of  glioma,
itself a rare entity, which may appear morpho-
logically identical, but are genetically distinct.
4
Further advancements in molecular pathology,
genomics,  proteomics  and  other  disciplines
may accelerate this trend towards individual
characterization  of  common  neoplasms  into
uncommon subtypes. 
Considerable  challenges  remain  in  rare
tumor  research.  Their  infrequency  makes
effective  study  more  difficult,  both  in  the
realms of basic and clinical research. Single
institutions and cooperative groups may find it
difficult to recruit sufficient patients to per-
form  adequately  powered  clinical  trials  that
can  concluded  in  a  meaningful  amount  of
time. Even when such barriers can be over-
come, those studying rare tumors are at a dis-
advantage when competing for grant funding
against  more  common  tumors  that  would
accrue to trials much quicker and in greater
numbers. In the hierarchy of evidence based
medicine, rare tumor study by necessity occurs
primarily below the level of randomized, dou-
ble blinded clinical trials. The lack of financial
incentives for the development of clinical trials
and drug therapies for small groups of patients
with rare disease has long been recognized.
The Orphan Drug Act in the United States and
similar  legislation  in  Europe  has  helped
address this dilemma in part. In the US, the
National Institutes of Health and the Office of
Rare Diseases fund the Rare Diseases Clinical
Research  Network  (http://rarediseasesnet-
work.epi.usf.edu/) a consortium of investiga-
tors whose goal is to identify biomarkers asso-
ciated with rare disease expression and pro-
mote new preventative, diagnostic and thera-
peutic interventions. In Europe, the European
Clinical  Research  Infrastructures  Network
(http://www.ecrin.org/) provides a similar sup-
portive  role.  Groups  such  as  the  Children’s
Oncology Group (http://www.childrensoncolo-
gygroup.org/) and the International Society of
Paediatric Oncology (http://www.siop.nl/) pro-
vide excellent models of the quality of research
that can be accomplished through national and
international collaboration in rare malignancy
study.  However,  similar  cooperative  mecha-
nisms have not yet evolved in the treatment of
adult rare malignancies. Large cohort and case
control studies are possible through national
registries and other existing databases such as
the  U.S.  National  Cancer  Institute’s
Surveillance  Epidemiology  and  End  Results
program  (http://www.seer.cancer.gov/).
5 Such
projects  can  provide  far  greater  statistical
power to define the incidence and natural his-
tory of rare tumors than institutional or coop-
erative group studies, but they are limited in
the insights they can provide into the genetic
classification  and  management  of  such
tumors.  Ad  hoc  networks  such  as  the  Rare
Cancer  Network  (http://www.rarecancer.net)
have effectively utilized internet based com-
munication to bring together a geographically
diverse  group  of  investigators  with  similar
interests in rare tumor study. 
In recent years, the role of patient advocacy
groups  has  grown  in  supporting  rare  tumor
research  and  in  affecting  public  policy.
National umbrella rare disease organizations
such  as  the  U.S.  National  Organization  for
Rare  Disorders  (http://www.rarediseases.org/)
and  EURODIS/Rare  Diseases  Europe
(http://www.eurordis.org/) provide their volun-
teer  member  organizations  with  access  to
patient  educational  and  advocacy  resources,
political  lobbying  and  funding  opportunities
that would be otherwise difficult to obtain for
small groups focused on a single disease enti-
ty. Patient advocacy organizations for rare dis-
eases  have  increasingly  begun  to  take  on  a
proactive role in uniting the efforts of patients,
researchers and governmental funding bodies.
An example of this trend in the field of rare
neoplasms  is  the  Chordoma  Foundation
(http://www.chordomafoundation.org/), a non-
profit  foundation  that  provides  funding  and
strategic direction for chordoma research, as
well as biospecimen bank, patient registry and
databank  resources,  to  a  multi-institutional,
international  collaboration  of  researchers,
while also providing direct patient education
and  support.  The  Chordoma  Foundation  has
outlined  a  five-step  strategic  plan  for  their
vision of the future of chordoma research. This
plan starts with resource development to pro-
vide the infrastructure for chordoma research
in its first phase, progresses to the molecular
classification of chordoma biology in its sec-
ond, and then moves on to identification of tar-
get  molecules  and  pathways  for  chordoma
therapy in its third phase. The fourth phase
consists of testing potential treatments in the
laboratory and the clinic, before beginning the
final  phase  of  clinical  trials  and  biomarker
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identification.
6 Such  a  program  provides  an
excellent model in rare tumor research for oth-
ers to emulate, which by necessity will require
multi-disciplinary collaboration on a national
and international basis. 
Despite  these  challenges,  rare  tumor
research can have important ramifications for
general oncological practice. Gastrointestinal
stromal tumors (GIST) are a rare tumor of the
gastrointestinal tract with a US annual inci-
dence  of  only  5,000  to  6,000  cases.
Characterization of the role of the proto-onco-
gene KIT in promoting the growth of GIST, fol-
lowed by the demonstration of the efficacy of
imatinib in treating GIST, facilitated the intro-
duction of small tyrosine kinase inhibitors into
the general treatment of solid tumors. The util-
ity of tyrosine kinase inhibitors is now being
defined in a wide variety of both rare and com-
mon neoplasms.
7,8
We wish to invite all researchers and clini-
cians who are involved in rare tumor research
and treatment to contribute their observations
on the problems of working in this field, either
as a letter to the editor, an editorial on a select
issue, or as a review paper. Information on the
submission process can be found on the Rare
Tumors website (http://www.pagepress.org/rt).
Those authors wishing to submit an editorial
or review should first contact our editorial staff
at  office@pagepress.org  to  discuss  the  suit-
ability of their topic. 
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